Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14324475 | 0.86 | CYP3A4 (0.44) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2402946 | 0.85 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL14764808 | 0.85 | CYP2C9 (0.39) | PTGES2CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2404008 | 0.84 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL14764310 | 0.84 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2401915 | 0.84 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2405050 | 0.84 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2403910 | 0.84 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2401937 | 0.84 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2296869 | 0.82 | CYP2C9 (0.49) | PTGES2CYP2C9CYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9265773-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-31 | — | — | US | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, HAVCR2, EIF2AK2 | PTGES2 1232/4885CYP2C9 520/4885CYP3A4 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.